METHYLPHENDATE AND ADHD: INFLUENCE OF AGE, IQ AND NEURODEVELOPMENTAL STATUS
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
SUMMARY: Sixty‐nine children with attention deficit hyperactivity disorder (ADHD) underwent blind methyl‐phenidate trials. 36 had ADHD alone (with or without a learning disability) and 33 had additional neurodevelopmental disorders. Of the children with ADHD alone, 88 per cent improved significantly on methylphenidate. This did not differ significantly from the 69 per cent response rate for children with ADHD and other neurodevelopmental disorders. The results confirm and add to the research literature indicating that ADHD children who are of preschool age and/or who have co‐existing neurological disorders may benefit from methylphenidate. RÉSUMÉ: Methylphénidate et ADHD: Influence de l'âge, du QI et de l'état neurodévelopmental Des essais aveugles de traitement par méthylphénidate ont été entrepris chez 69 enfants presentant un trouble de déficit d'attention et hyperactivity (ADHD). Dans 36 cas l'ADHD était isote avec ou sans trouble des apprentissages et dans les 33 cas restant, il y avait en plus des troubles neurodévelopmentaux (ND). Parmi les enfants avec ADHD isolé, 88 pour cent furent améliorés significativement par le méthylphénidate. Ceci ne différait pas significativement du 69 pour cent taux de réponses chez les enfants avec ADHD etc d'autres troubles ND. Ces résultats confirment et s'ajouterit aux données de la littérature indiquant que les enfants ADHD d'âge préscolaire avec ou sans trouble neurologique coexistant peuvent bénéficicr du méthylphénidate. ZUSAMMENFASSUNG: Methylphenidat und ADHD: Einfluß von Alter, IQ und entwicklungsneurologischem Befund Bei 69 Kindern mit Aufmerksamkeitsstörungen und Hyperaktivität (ADHD) wurden blinde Behandlungsversuche mit Methylphenidat durchgeführt. 36 Kindern hatten nur eine ADHD (mit Oder ohne Lernschwäche) und 33 hatten zusätzlich entwicklungsneurologische (ND) Störungen. Von den Kindern mit ADHD allein zeigten 88 Prozent eine signifikante Besserung auf Methylphenidat. Es bestand kein signifikanter Unterschied zur 69 Prozent Ansprechrate der Kinder mit ADHD und andercn ND Störungen. Die Ergebnisse bestätigen und ergänzen die wissenschaftliche Literatur dahingehend, daß Vorschulkinder mit ADHD und/oder mit gleichzeitig bestehenden neurologischen Erkrankungen von der Behandlung mit Methylphenidat profitieren. RESUMEN: Metilfenidato y ADHD: influencia de la edad, CI y estatus neuroevolutivo Sesenta y nueve niños con alteración de la atencion e hiperactividad (AAH, ADHD en inglés) fueron sometidos a una prueba con metilfenidato ciega. 36 tenian solo AAH (con o sin dificultad para el aprendizaje) y 33 tenian además alteraciones del desarrollo (AD). De los niños con AAH solo, 88 por ciento mejoraron significativamente con el metilfenidato. Esta respuesta no diferia significativamente del promedio de respuesta 69 por ciento en niños con AAH y otra alteracion del desarrollo (AD). Los resultados confirman y coadyuvan a la literatura indicando que los niños, con AAH en edad preescolar y/o una alteración neurológica coexistente pueden beneficiarse del metilfenidato.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A controlled trial of stimulant medication in children with the fragile X syndrome
Hagerman, R. J., Murphy, M. A., & Wittenberger, M. D. (1988) · American Journal of Medical Genetics · doi:10.1002/ajmg.1320300138 · Cited by 158
Cited by
Greenhill, L. L., Pliszka, S., & Dulcan, M. K. (2002) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200202001-00003 · Cited by 927
Pharmacotherapy of Attention-Deficit Hyperactivity Disorder across the Life Cycle
SPENCER, T., BIEDERMAN, J., WILENS, T., HARDING, M., O'DONNELL, D., & GRIFFIN, S. (1996) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199604000-00008 · Cited by 830
Gillberg, C. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830210105014 · Cited by 340
Storebø, O. J., Pedersen, N., Ramstad, E., Kielsholm, M. L., Nielsen, S. S., Krogh, H. B., Moreira-Maia, C. R., Magnusson, F. L., Holmskov, M., Gerner, T., et al. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012069.pub2 · Cited by 321
Mayes, S. D., & Calhoun, S. L. (2003) · Journal of Autism and Developmental Disorders · doi:10.1023/a:1024462719081 · Cited by 319
“Research studies of children with attention deficit hyperactivity disorder (ADHD) show that Freedom from Distractibility followed by Processing Speed are the lowest WISC-III Index scores (Anastopoulos, Spisto, & Maher, 1994; Mayes, Calhoun, & Crowell, 1998; Mealer, Morgan, & Luscomb, 1996; Prifitera & Dersh, 1993).”
BackgroundSelf-citation
Metadata
- Authors
- Mayes, S. D., Crites, D. L., Bixler, E. O., Humphrey, F. J., & Maltison, R. E.
- Venue
- Developmental Medicine & Child Neurology
- Publisher
- Wiley
- Published
- 1994-12
- Volume
- 36
- Issue
- 12
- Pages
- 1099-1107
- ISSN
- 0012-1622 (ISSN-L)
- 1469-8749
- OpenAlex
- W1991614460
- Cited by
- 70
- References
- 1
- FWCI
- 1.45
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: METHYLPHENDATE AND ADHD: INFLUENCE OF AGE, IQ AND NEURODEVELOPMENTAL STATUS. https://app.cochat.ai/papers/10.1111/j.1469-8749.1994.tb11811.x
- The paper
- Mayes, S. D., Crites, D. L., Bixler, E. O., Humphrey, F. J., & Maltison, R. E. (1994). METHYLPHENDATE AND ADHD: INFLUENCE OF AGE, IQ AND NEURODEVELOPMENTAL STATUS. Developmental Medicine & Child Neurology. https://doi.org/10.1111/j.1469-8749.1994.tb11811.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.